nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—Tinnitus—Sorafenib—liver cancer	0.00559	0.00572	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Sorafenib—liver cancer	0.00556	0.00569	CcSEcCtD
Zuclopenthixol—Ventricular arrhythmia—Doxorubicin—liver cancer	0.00552	0.00564	CcSEcCtD
Zuclopenthixol—Glycosuria—Epirubicin—liver cancer	0.00545	0.00557	CcSEcCtD
Zuclopenthixol—Angiopathy—Sorafenib—liver cancer	0.00544	0.00557	CcSEcCtD
Zuclopenthixol—Immune system disorder—Sorafenib—liver cancer	0.00542	0.00554	CcSEcCtD
Zuclopenthixol—Arrhythmia—Sorafenib—liver cancer	0.00536	0.00548	CcSEcCtD
Zuclopenthixol—Mental disorder—Sorafenib—liver cancer	0.00525	0.00537	CcSEcCtD
Zuclopenthixol—Malnutrition—Sorafenib—liver cancer	0.00522	0.00534	CcSEcCtD
Zuclopenthixol—Erythema—Sorafenib—liver cancer	0.00522	0.00534	CcSEcCtD
Zuclopenthixol—Feeling hot—Doxorubicin—liver cancer	0.0052	0.00532	CcSEcCtD
Zuclopenthixol—Glycosuria—Doxorubicin—liver cancer	0.00504	0.00516	CcSEcCtD
Zuclopenthixol—Amenorrhoea—Epirubicin—liver cancer	0.00502	0.00514	CcSEcCtD
Zuclopenthixol—Skin discolouration—Epirubicin—liver cancer	0.00488	0.005	CcSEcCtD
Zuclopenthixol—Dyskinesia—Epirubicin—liver cancer	0.00469	0.0048	CcSEcCtD
Zuclopenthixol—Syncope—Sorafenib—liver cancer	0.00468	0.00479	CcSEcCtD
Zuclopenthixol—Leukopenia—Sorafenib—liver cancer	0.00467	0.00478	CcSEcCtD
Zuclopenthixol—Blood bilirubin increased—Epirubicin—liver cancer	0.00466	0.00477	CcSEcCtD
Zuclopenthixol—Amenorrhoea—Doxorubicin—liver cancer	0.00465	0.00475	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Sorafenib—liver cancer	0.00459	0.00469	CcSEcCtD
Zuclopenthixol—Gait disturbance—Epirubicin—liver cancer	0.00452	0.00463	CcSEcCtD
Zuclopenthixol—Skin discolouration—Doxorubicin—liver cancer	0.00452	0.00462	CcSEcCtD
Zuclopenthixol—Hypertension—Sorafenib—liver cancer	0.00451	0.00461	CcSEcCtD
Zuclopenthixol—Myalgia—Sorafenib—liver cancer	0.00444	0.00455	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00441	0.00451	CcSEcCtD
Zuclopenthixol—Ventricular tachycardia—Epirubicin—liver cancer	0.00441	0.00451	CcSEcCtD
Zuclopenthixol—Injection site reaction—Epirubicin—liver cancer	0.00439	0.00449	CcSEcCtD
Zuclopenthixol—Abnormal dreams—Epirubicin—liver cancer	0.00436	0.00446	CcSEcCtD
Zuclopenthixol—Dry mouth—Sorafenib—liver cancer	0.00435	0.00445	CcSEcCtD
Zuclopenthixol—Dyskinesia—Doxorubicin—liver cancer	0.00434	0.00444	CcSEcCtD
Zuclopenthixol—Blood bilirubin increased—Doxorubicin—liver cancer	0.00432	0.00442	CcSEcCtD
Zuclopenthixol—Salivary hypersecretion—Epirubicin—liver cancer	0.00428	0.00438	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Sorafenib—liver cancer	0.00426	0.00436	CcSEcCtD
Zuclopenthixol—Shock—Sorafenib—liver cancer	0.00419	0.00429	CcSEcCtD
Zuclopenthixol—Gait disturbance—Doxorubicin—liver cancer	0.00418	0.00428	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Sorafenib—liver cancer	0.00418	0.00427	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Sorafenib—liver cancer	0.00417	0.00427	CcSEcCtD
Zuclopenthixol—Skin disorder—Sorafenib—liver cancer	0.00414	0.00423	CcSEcCtD
Zuclopenthixol—Ventricular tachycardia—Doxorubicin—liver cancer	0.00408	0.00418	CcSEcCtD
Zuclopenthixol—Anorexia—Sorafenib—liver cancer	0.00406	0.00415	CcSEcCtD
Zuclopenthixol—Injection site reaction—Doxorubicin—liver cancer	0.00406	0.00415	CcSEcCtD
Zuclopenthixol—Abnormal dreams—Doxorubicin—liver cancer	0.00403	0.00413	CcSEcCtD
Zuclopenthixol—Salivary hypersecretion—Doxorubicin—liver cancer	0.00396	0.00406	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00388	0.00397	CcSEcCtD
Zuclopenthixol—Hypertonia—Epirubicin—liver cancer	0.00387	0.00396	CcSEcCtD
Zuclopenthixol—Abnormal vision—Epirubicin—liver cancer	0.00385	0.00394	CcSEcCtD
Zuclopenthixol—Dyspnoea—Sorafenib—liver cancer	0.0038	0.00389	CcSEcCtD
Zuclopenthixol—Dyspepsia—Sorafenib—liver cancer	0.00375	0.00384	CcSEcCtD
Zuclopenthixol—Decreased appetite—Sorafenib—liver cancer	0.0037	0.00379	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Sorafenib—liver cancer	0.00368	0.00376	CcSEcCtD
Zuclopenthixol—Fatigue—Sorafenib—liver cancer	0.00367	0.00376	CcSEcCtD
Zuclopenthixol—Pain—Sorafenib—liver cancer	0.00364	0.00373	CcSEcCtD
Zuclopenthixol—Constipation—Sorafenib—liver cancer	0.00364	0.00373	CcSEcCtD
Zuclopenthixol—Vascular purpura—Epirubicin—liver cancer	0.00358	0.00366	CcSEcCtD
Zuclopenthixol—Hypertonia—Doxorubicin—liver cancer	0.00358	0.00366	CcSEcCtD
Zuclopenthixol—Abnormal vision—Doxorubicin—liver cancer	0.00356	0.00364	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Sorafenib—liver cancer	0.00348	0.00356	CcSEcCtD
Zuclopenthixol—Hot flush—Epirubicin—liver cancer	0.00342	0.0035	CcSEcCtD
Zuclopenthixol—Increased appetite—Epirubicin—liver cancer	0.00341	0.00349	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Epirubicin—liver cancer	0.00339	0.00347	CcSEcCtD
Zuclopenthixol—Abdominal pain—Sorafenib—liver cancer	0.00337	0.00345	CcSEcCtD
Zuclopenthixol—Body temperature increased—Sorafenib—liver cancer	0.00337	0.00345	CcSEcCtD
Zuclopenthixol—Purpura—Epirubicin—liver cancer	0.00332	0.0034	CcSEcCtD
Zuclopenthixol—Vascular purpura—Doxorubicin—liver cancer	0.00331	0.00339	CcSEcCtD
Zuclopenthixol—Hot flush—Doxorubicin—liver cancer	0.00317	0.00324	CcSEcCtD
Zuclopenthixol—Increased appetite—Doxorubicin—liver cancer	0.00315	0.00323	CcSEcCtD
Zuclopenthixol—Migraine—Epirubicin—liver cancer	0.00315	0.00323	CcSEcCtD
Zuclopenthixol—Menopausal symptoms—Doxorubicin—liver cancer	0.00314	0.00321	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Sorafenib—liver cancer	0.00314	0.00321	CcSEcCtD
Zuclopenthixol—Purpura—Doxorubicin—liver cancer	0.00307	0.00315	CcSEcCtD
Zuclopenthixol—Asthenia—Sorafenib—liver cancer	0.00306	0.00313	CcSEcCtD
Zuclopenthixol—Pruritus—Sorafenib—liver cancer	0.00301	0.00308	CcSEcCtD
Zuclopenthixol—Ataxia—Epirubicin—liver cancer	0.00301	0.00308	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Epirubicin—liver cancer	0.00296	0.00303	CcSEcCtD
Zuclopenthixol—Migraine—Doxorubicin—liver cancer	0.00292	0.00298	CcSEcCtD
Zuclopenthixol—Diarrhoea—Sorafenib—liver cancer	0.00291	0.00298	CcSEcCtD
Zuclopenthixol—Breast disorder—Epirubicin—liver cancer	0.00289	0.00296	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Epirubicin—liver cancer	0.00286	0.00293	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00282	0.00289	CcSEcCtD
Zuclopenthixol—Dizziness—Sorafenib—liver cancer	0.00282	0.00288	CcSEcCtD
Zuclopenthixol—Ataxia—Doxorubicin—liver cancer	0.00279	0.00285	CcSEcCtD
Zuclopenthixol—Eosinophilia—Epirubicin—liver cancer	0.00274	0.0028	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Doxorubicin—liver cancer	0.00274	0.0028	CcSEcCtD
Zuclopenthixol—Vomiting—Sorafenib—liver cancer	0.00271	0.00277	CcSEcCtD
Zuclopenthixol—Rash—Sorafenib—liver cancer	0.00269	0.00275	CcSEcCtD
Zuclopenthixol—Dermatitis—Sorafenib—liver cancer	0.00268	0.00275	CcSEcCtD
Zuclopenthixol—Breast disorder—Doxorubicin—liver cancer	0.00268	0.00274	CcSEcCtD
Zuclopenthixol—Headache—Sorafenib—liver cancer	0.00267	0.00273	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Doxorubicin—liver cancer	0.00265	0.00271	CcSEcCtD
Zuclopenthixol—Pancytopenia—Epirubicin—liver cancer	0.00263	0.00269	CcSEcCtD
Zuclopenthixol—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00261	0.00267	CcSEcCtD
Zuclopenthixol—Dysuria—Epirubicin—liver cancer	0.00259	0.00265	CcSEcCtD
Zuclopenthixol—Neutropenia—Epirubicin—liver cancer	0.00259	0.00265	CcSEcCtD
Zuclopenthixol—Eosinophilia—Doxorubicin—liver cancer	0.00254	0.00259	CcSEcCtD
Zuclopenthixol—Nausea—Sorafenib—liver cancer	0.00253	0.00259	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Epirubicin—liver cancer	0.00253	0.00259	CcSEcCtD
Zuclopenthixol—Weight increased—Epirubicin—liver cancer	0.00252	0.00258	CcSEcCtD
Zuclopenthixol—Weight decreased—Epirubicin—liver cancer	0.0025	0.00256	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Epirubicin—liver cancer	0.0025	0.00255	CcSEcCtD
Zuclopenthixol—Drowsiness—Epirubicin—liver cancer	0.00247	0.00253	CcSEcCtD
Zuclopenthixol—Pancytopenia—Doxorubicin—liver cancer	0.00243	0.00249	CcSEcCtD
Zuclopenthixol—Jaundice—Epirubicin—liver cancer	0.00241	0.00246	CcSEcCtD
Zuclopenthixol—Dysuria—Doxorubicin—liver cancer	0.0024	0.00245	CcSEcCtD
Zuclopenthixol—Neutropenia—Doxorubicin—liver cancer	0.0024	0.00245	CcSEcCtD
Zuclopenthixol—Sweating—Epirubicin—liver cancer	0.00237	0.00242	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Doxorubicin—liver cancer	0.00234	0.00239	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Epirubicin—liver cancer	0.00233	0.00239	CcSEcCtD
Zuclopenthixol—Weight increased—Doxorubicin—liver cancer	0.00233	0.00239	CcSEcCtD
Zuclopenthixol—Weight decreased—Doxorubicin—liver cancer	0.00232	0.00237	CcSEcCtD
Zuclopenthixol—Hyperglycaemia—Doxorubicin—liver cancer	0.00231	0.00236	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Epirubicin—liver cancer	0.0023	0.00236	CcSEcCtD
Zuclopenthixol—Drowsiness—Doxorubicin—liver cancer	0.00228	0.00234	CcSEcCtD
Zuclopenthixol—Jaundice—Doxorubicin—liver cancer	0.00223	0.00228	CcSEcCtD
Zuclopenthixol—Sweating—Doxorubicin—liver cancer	0.00219	0.00224	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Epirubicin—liver cancer	0.00219	0.00224	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Epirubicin—liver cancer	0.00218	0.00223	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Epirubicin—liver cancer	0.00218	0.00223	CcSEcCtD
Zuclopenthixol—Urethral disorder—Epirubicin—liver cancer	0.00217	0.00222	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Doxorubicin—liver cancer	0.00216	0.00221	CcSEcCtD
Zuclopenthixol—Visual impairment—Epirubicin—liver cancer	0.00214	0.00218	CcSEcCtD
Zuclopenthixol—Agranulocytosis—Doxorubicin—liver cancer	0.00213	0.00218	CcSEcCtD
Zuclopenthixol—Eye disorder—Epirubicin—liver cancer	0.00207	0.00212	CcSEcCtD
Zuclopenthixol—Tinnitus—Epirubicin—liver cancer	0.00207	0.00211	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Epirubicin—liver cancer	0.00206	0.0021	CcSEcCtD
Zuclopenthixol—Urinary tract disorder—Doxorubicin—liver cancer	0.00202	0.00207	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Doxorubicin—liver cancer	0.00202	0.00207	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Doxorubicin—liver cancer	0.00201	0.00206	CcSEcCtD
Zuclopenthixol—Angiopathy—Epirubicin—liver cancer	0.00201	0.00206	CcSEcCtD
Zuclopenthixol—Urethral disorder—Doxorubicin—liver cancer	0.00201	0.00206	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—liver cancer	0.002	0.00205	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—liver cancer	0.00198	0.00203	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—liver cancer	0.00198	0.00202	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—liver cancer	0.00194	0.00199	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—liver cancer	0.00193	0.00197	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—liver cancer	0.00193	0.00197	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—liver cancer	0.00192	0.00196	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—liver cancer	0.00191	0.00196	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—liver cancer	0.0019	0.00195	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—liver cancer	0.0019	0.00194	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—liver cancer	0.00189	0.00194	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—liver cancer	0.00187	0.00192	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—liver cancer	0.00186	0.0019	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—liver cancer	0.00185	0.00189	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—liver cancer	0.00183	0.00187	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—liver cancer	0.00182	0.00186	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—liver cancer	0.0018	0.00184	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—liver cancer	0.00179	0.00183	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—liver cancer	0.00178	0.00183	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—liver cancer	0.00178	0.00183	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—liver cancer	0.00177	0.00181	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—liver cancer	0.00176	0.0018	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—liver cancer	0.00175	0.00179	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—liver cancer	0.00174	0.00178	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—liver cancer	0.00173	0.00177	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—liver cancer	0.00173	0.00177	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—liver cancer	0.00173	0.00177	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—liver cancer	0.00173	0.00177	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—liver cancer	0.0017	0.00174	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—liver cancer	0.0017	0.00173	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—liver cancer	0.00168	0.00172	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—liver cancer	0.00167	0.00171	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—liver cancer	0.00167	0.0017	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—liver cancer	0.00166	0.00169	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—liver cancer	0.00164	0.00168	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—liver cancer	0.00164	0.00168	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—liver cancer	0.00164	0.00167	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00163	0.00167	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—liver cancer	0.00162	0.00166	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—liver cancer	0.00161	0.00165	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—liver cancer	0.00161	0.00164	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—liver cancer	0.0016	0.00164	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—liver cancer	0.0016	0.00164	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—liver cancer	0.0016	0.00163	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—liver cancer	0.00158	0.00161	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—liver cancer	0.00157	0.00161	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—liver cancer	0.00157	0.0016	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—liver cancer	0.00155	0.00158	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—liver cancer	0.00155	0.00158	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—liver cancer	0.00154	0.00158	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—liver cancer	0.00154	0.00158	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—liver cancer	0.00154	0.00158	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—liver cancer	0.00154	0.00157	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—liver cancer	0.00153	0.00156	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—liver cancer	0.00152	0.00156	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—liver cancer	0.00152	0.00155	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—liver cancer	0.00151	0.00155	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00151	0.00154	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—liver cancer	0.0015	0.00154	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—liver cancer	0.0015	0.00154	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—liver cancer	0.00149	0.00152	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—liver cancer	0.00147	0.00151	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—liver cancer	0.00146	0.00149	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00143	0.00147	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—liver cancer	0.00143	0.00147	CcSEcCtD
Zuclopenthixol—Fluphenazine—CYP2E1—liver cancer	0.00143	0.165	CrCbGaD
Zuclopenthixol—Nervous system disorder—Doxorubicin—liver cancer	0.00143	0.00146	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—liver cancer	0.00143	0.00146	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—liver cancer	0.00142	0.00146	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—liver cancer	0.00142	0.00145	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—liver cancer	0.00141	0.00145	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—liver cancer	0.00141	0.00145	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—liver cancer	0.00141	0.00144	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—liver cancer	0.0014	0.00144	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—liver cancer	0.0014	0.00143	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—liver cancer	0.00139	0.00142	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—liver cancer	0.00139	0.00142	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—liver cancer	0.00137	0.0014	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—liver cancer	0.00136	0.00139	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—liver cancer	0.00136	0.00139	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—liver cancer	0.00136	0.00139	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—liver cancer	0.00135	0.00138	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—liver cancer	0.00135	0.00138	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00133	0.00136	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—liver cancer	0.00132	0.00135	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—liver cancer	0.00131	0.00134	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—liver cancer	0.0013	0.00133	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—liver cancer	0.0013	0.00133	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—liver cancer	0.00129	0.00132	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—liver cancer	0.00129	0.00132	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—liver cancer	0.00128	0.00131	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—liver cancer	0.00127	0.0013	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00126	0.00129	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—liver cancer	0.00126	0.00128	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—liver cancer	0.00125	0.00127	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—liver cancer	0.00125	0.00127	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—liver cancer	0.00124	0.00127	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—liver cancer	0.00124	0.00127	CcSEcCtD
Zuclopenthixol—Thioridazine—CYP2E1—liver cancer	0.00123	0.142	CrCbGaD
Zuclopenthixol—Feeling abnormal—Doxorubicin—liver cancer	0.0012	0.00123	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—liver cancer	0.00119	0.00122	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—liver cancer	0.00116	0.00119	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—liver cancer	0.00115	0.00118	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—liver cancer	0.00115	0.00118	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—liver cancer	0.00113	0.00116	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—liver cancer	0.00111	0.00114	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—liver cancer	0.00108	0.0011	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—liver cancer	0.00107	0.0011	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—liver cancer	0.00105	0.00107	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—liver cancer	0.00104	0.00107	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—liver cancer	0.00103	0.00105	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—liver cancer	0.001	0.00102	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—liver cancer	0.000997	0.00102	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—liver cancer	0.000993	0.00102	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—liver cancer	0.000992	0.00101	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—liver cancer	0.000986	0.00101	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—liver cancer	0.000963	0.000986	CcSEcCtD
Zuclopenthixol—Clozapine—CYP2E1—liver cancer	0.000955	0.11	CrCbGaD
Zuclopenthixol—Clozapine—CYP1A1—liver cancer	0.000942	0.108	CrCbGaD
Zuclopenthixol—Nausea—Epirubicin—liver cancer	0.000935	0.000957	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—liver cancer	0.000926	0.000948	CcSEcCtD
Zuclopenthixol—Thioproperazine—ALB—liver cancer	0.000925	0.106	CrCbGaD
Zuclopenthixol—Rash—Doxorubicin—liver cancer	0.000918	0.00094	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—liver cancer	0.000918	0.000939	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—liver cancer	0.000912	0.000934	CcSEcCtD
Zuclopenthixol—Pipotiazine—ALB—liver cancer	0.00091	0.105	CrCbGaD
Zuclopenthixol—Thiothixene—ALB—liver cancer	0.00091	0.105	CrCbGaD
Zuclopenthixol—Chlorpromazine—CYP2E1—liver cancer	0.000898	0.103	CrCbGaD
Zuclopenthixol—Nausea—Doxorubicin—liver cancer	0.000865	0.000885	CcSEcCtD
Zuclopenthixol—Chlorpromazine—ALB—liver cancer	0.000493	0.0567	CrCbGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KDR—liver cancer	4.06e-06	0.00029	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CTNNB1—liver cancer	4.05e-06	0.00029	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—F2—liver cancer	4.05e-06	0.00029	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ESR1—liver cancer	4.04e-06	0.000289	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—RAF1—liver cancer	4.03e-06	0.000289	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK14—liver cancer	4.03e-06	0.000288	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ESR1—liver cancer	4.03e-06	0.000288	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PPARG—liver cancer	4.01e-06	0.000287	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—F2—liver cancer	3.99e-06	0.000285	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—F2—liver cancer	3.98e-06	0.000285	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MMP9—liver cancer	3.97e-06	0.000284	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTP1—liver cancer	3.97e-06	0.000284	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CDKN1A—liver cancer	3.96e-06	0.000283	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ESR1—liver cancer	3.95e-06	0.000283	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CB—liver cancer	3.94e-06	0.000282	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MTOR—liver cancer	3.94e-06	0.000282	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—KRAS—liver cancer	3.93e-06	0.000281	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HMOX1—liver cancer	3.91e-06	0.00028	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—AKT1—liver cancer	3.91e-06	0.00028	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—F2—liver cancer	3.9e-06	0.000279	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CG—liver cancer	3.88e-06	0.000278	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APC—liver cancer	3.88e-06	0.000278	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK8—liver cancer	3.87e-06	0.000277	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—AKT1—liver cancer	3.85e-06	0.000276	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CG—liver cancer	3.82e-06	0.000273	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APC—liver cancer	3.82e-06	0.000273	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APC—liver cancer	3.81e-06	0.000273	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CG—liver cancer	3.81e-06	0.000273	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KDR—liver cancer	3.77e-06	0.00027	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—HRAS—liver cancer	3.76e-06	0.000269	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK14—liver cancer	3.74e-06	0.000268	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APC—liver cancer	3.74e-06	0.000267	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CG—liver cancer	3.74e-06	0.000267	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDKN1B—liver cancer	3.69e-06	0.000264	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ESR1—liver cancer	3.67e-06	0.000263	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—AKT1—liver cancer	3.65e-06	0.000262	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CD—liver cancer	3.65e-06	0.000261	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—BRAF—liver cancer	3.65e-06	0.000261	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTM1—liver cancer	3.64e-06	0.000261	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—F2—liver cancer	3.63e-06	0.00026	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CASP3—liver cancer	3.62e-06	0.000259	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL2—liver cancer	3.62e-06	0.000259	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—PIK3CA—liver cancer	3.61e-06	0.000258	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ALB—liver cancer	3.6e-06	0.000258	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—IL6—liver cancer	3.6e-06	0.000257	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—BRAF—liver cancer	3.59e-06	0.000257	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—BRAF—liver cancer	3.58e-06	0.000256	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—VEGFA—liver cancer	3.57e-06	0.000255	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—STAT3—liver cancer	3.53e-06	0.000253	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCND1—liver cancer	3.52e-06	0.000252	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—JUN—liver cancer	3.52e-06	0.000252	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—BRAF—liver cancer	3.51e-06	0.000251	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—liver cancer	3.49e-06	0.00025	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CTNNB1—liver cancer	3.49e-06	0.00025	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APC—liver cancer	3.47e-06	0.000248	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CG—liver cancer	3.47e-06	0.000248	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP1A1—liver cancer	3.45e-06	0.000247	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—liver cancer	3.42e-06	0.000245	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CD—liver cancer	3.41e-06	0.000244	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDKN1A—liver cancer	3.41e-06	0.000244	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—PIK3CA—liver cancer	3.38e-06	0.000242	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SERPINE1—liver cancer	3.37e-06	0.000241	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CD—liver cancer	3.35e-06	0.00024	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CD—liver cancer	3.35e-06	0.00024	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HRAS—liver cancer	3.34e-06	0.000239	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KRAS—liver cancer	3.34e-06	0.000239	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK8—liver cancer	3.33e-06	0.000238	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	3.32e-06	0.000238	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—liver cancer	3.32e-06	0.000237	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SERPINE1—liver cancer	3.32e-06	0.000237	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—PIK3CA—liver cancer	3.32e-06	0.000237	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SERPINE1—liver cancer	3.31e-06	0.000237	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CD—liver cancer	3.28e-06	0.000235	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KRAS—liver cancer	3.28e-06	0.000235	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—liver cancer	3.28e-06	0.000235	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KRAS—liver cancer	3.28e-06	0.000235	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFB1—liver cancer	3.28e-06	0.000234	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—BRAF—liver cancer	3.26e-06	0.000234	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—PIK3CA—liver cancer	3.25e-06	0.000233	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SERPINE1—liver cancer	3.25e-06	0.000233	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—MTHFR—liver cancer	3.22e-06	0.00023	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KRAS—liver cancer	3.22e-06	0.00023	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—liver cancer	3.2e-06	0.000229	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CB—liver cancer	3.18e-06	0.000228	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARA—liver cancer	3.16e-06	0.000226	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—liver cancer	3.07e-06	0.00022	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PIK3CA—liver cancer	3.07e-06	0.000219	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	3.05e-06	0.000218	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—RAF1—liver cancer	3.04e-06	0.000218	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—STAT3—liver cancer	3.04e-06	0.000218	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KRAS—liver cancer	3.03e-06	0.000217	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	3.02e-06	0.000216	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	3.02e-06	0.000216	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	3.02e-06	0.000216	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PIK3CA—liver cancer	3.01e-06	0.000215	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—RAF1—liver cancer	3e-06	0.000214	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—RAF1—liver cancer	2.99e-06	0.000214	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KRAS—liver cancer	2.99e-06	0.000214	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MTOR—liver cancer	2.97e-06	0.000213	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CB—liver cancer	2.97e-06	0.000213	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	2.95e-06	0.000211	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—liver cancer	2.95e-06	0.000211	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—RAF1—liver cancer	2.93e-06	0.00021	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MTOR—liver cancer	2.92e-06	0.000209	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CB—liver cancer	2.92e-06	0.000209	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MTOR—liver cancer	2.92e-06	0.000209	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CB—liver cancer	2.92e-06	0.000209	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MTOR—liver cancer	2.86e-06	0.000205	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	2.86e-06	0.000205	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HRAS—liver cancer	2.84e-06	0.000203	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—liver cancer	2.83e-06	0.000202	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFB1—liver cancer	2.82e-06	0.000202	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—HRAS—liver cancer	2.79e-06	0.0002	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1B—liver cancer	2.79e-06	0.0002	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PIK3CA—liver cancer	2.79e-06	0.000199	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HRAS—liver cancer	2.79e-06	0.000199	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—liver cancer	2.76e-06	0.000197	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	2.75e-06	0.000196	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1B—liver cancer	2.74e-06	0.000196	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1B—liver cancer	2.74e-06	0.000196	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HRAS—liver cancer	2.73e-06	0.000196	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—liver cancer	2.73e-06	0.000196	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL2—liver cancer	2.73e-06	0.000195	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—RAF1—liver cancer	2.72e-06	0.000195	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—liver cancer	2.72e-06	0.000194	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—liver cancer	2.71e-06	0.000194	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—liver cancer	2.71e-06	0.000194	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CG—liver cancer	2.71e-06	0.000194	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—liver cancer	2.7e-06	0.000193	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—liver cancer	2.69e-06	0.000192	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	2.69e-06	0.000192	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL2—liver cancer	2.69e-06	0.000192	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—liver cancer	2.68e-06	0.000192	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL2—liver cancer	2.68e-06	0.000192	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—liver cancer	2.67e-06	0.000191	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—liver cancer	2.67e-06	0.000191	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—liver cancer	2.66e-06	0.00019	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MTOR—liver cancer	2.66e-06	0.00019	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	2.66e-06	0.00019	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	2.66e-06	0.00019	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—JUN—liver cancer	2.66e-06	0.00019	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CTNNB1—liver cancer	2.63e-06	0.000189	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—liver cancer	2.63e-06	0.000188	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL2—liver cancer	2.63e-06	0.000188	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—liver cancer	2.62e-06	0.000187	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—liver cancer	2.62e-06	0.000187	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—JUN—liver cancer	2.61e-06	0.000187	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—liver cancer	2.61e-06	0.000187	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KRAS—liver cancer	2.61e-06	0.000187	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARG—liver cancer	2.61e-06	0.000187	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—JUN—liver cancer	2.61e-06	0.000187	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CTNNB1—liver cancer	2.59e-06	0.000186	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CTNNB1—liver cancer	2.59e-06	0.000185	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—liver cancer	2.58e-06	0.000185	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HRAS—liver cancer	2.58e-06	0.000185	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1A—liver cancer	2.57e-06	0.000184	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—liver cancer	2.56e-06	0.000183	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—JUN—liver cancer	2.56e-06	0.000183	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—liver cancer	2.54e-06	0.000182	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HRAS—liver cancer	2.54e-06	0.000182	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	2.54e-06	0.000182	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—liver cancer	2.54e-06	0.000182	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1A—liver cancer	2.53e-06	0.000181	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1A—liver cancer	2.53e-06	0.000181	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK8—liver cancer	2.51e-06	0.00018	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—liver cancer	2.51e-06	0.000179	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	2.5e-06	0.000179	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—liver cancer	2.49e-06	0.000178	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	2.48e-06	0.000177	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK8—liver cancer	2.47e-06	0.000177	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	2.47e-06	0.000177	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—liver cancer	2.47e-06	0.000177	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK8—liver cancer	2.47e-06	0.000177	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—liver cancer	2.47e-06	0.000176	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—liver cancer	2.46e-06	0.000176	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—liver cancer	2.45e-06	0.000175	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL2—liver cancer	2.44e-06	0.000175	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—liver cancer	2.43e-06	0.000174	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK8—liver cancer	2.42e-06	0.000173	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—liver cancer	2.41e-06	0.000173	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CA—liver cancer	2.4e-06	0.000172	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—liver cancer	2.38e-06	0.00017	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CD—liver cancer	2.38e-06	0.00017	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JUN—liver cancer	2.38e-06	0.00017	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	2.36e-06	0.000169	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—liver cancer	2.35e-06	0.000168	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—liver cancer	2.32e-06	0.000166	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—liver cancer	2.32e-06	0.000166	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—liver cancer	2.31e-06	0.000165	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	2.3e-06	0.000165	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—STAT3—liver cancer	2.3e-06	0.000164	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—liver cancer	2.28e-06	0.000163	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—liver cancer	2.28e-06	0.000163	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—liver cancer	2.28e-06	0.000163	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—STAT3—liver cancer	2.26e-06	0.000162	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—STAT3—liver cancer	2.26e-06	0.000161	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK8—liver cancer	2.25e-06	0.000161	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—liver cancer	2.24e-06	0.00016	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—liver cancer	2.23e-06	0.00016	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HRAS—liver cancer	2.22e-06	0.000159	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—STAT3—liver cancer	2.21e-06	0.000158	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—liver cancer	2.13e-06	0.000153	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFB1—liver cancer	2.13e-06	0.000152	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—liver cancer	2.12e-06	0.000152	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—liver cancer	2.1e-06	0.00015	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—liver cancer	2.1e-06	0.00015	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFB1—liver cancer	2.09e-06	0.00015	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFB1—liver cancer	2.09e-06	0.00015	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—liver cancer	2.08e-06	0.000149	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CB—liver cancer	2.07e-06	0.000148	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—liver cancer	2.06e-06	0.000147	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—STAT3—liver cancer	2.06e-06	0.000147	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFB1—liver cancer	2.05e-06	0.000147	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KRAS—liver cancer	1.97e-06	0.000141	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—liver cancer	1.96e-06	0.00014	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KRAS—liver cancer	1.94e-06	0.000139	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CA—liver cancer	1.94e-06	0.000139	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KRAS—liver cancer	1.94e-06	0.000139	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—liver cancer	1.91e-06	0.000137	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFB1—liver cancer	1.91e-06	0.000136	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KRAS—liver cancer	1.9e-06	0.000136	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CA—liver cancer	1.81e-06	0.00013	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CA—liver cancer	1.78e-06	0.000128	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CA—liver cancer	1.78e-06	0.000127	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KRAS—liver cancer	1.77e-06	0.000126	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—liver cancer	1.75e-06	0.000125	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	1.75e-06	0.000125	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—liver cancer	1.72e-06	0.000123	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—liver cancer	1.72e-06	0.000123	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—liver cancer	1.69e-06	0.000121	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HRAS—liver cancer	1.68e-06	0.00012	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HRAS—liver cancer	1.65e-06	0.000118	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HRAS—liver cancer	1.65e-06	0.000118	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	1.62e-06	0.000116	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HRAS—liver cancer	1.61e-06	0.000116	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—liver cancer	1.6e-06	0.000115	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—liver cancer	1.58e-06	0.000113	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—liver cancer	1.58e-06	0.000113	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—liver cancer	1.58e-06	0.000113	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—liver cancer	1.57e-06	0.000112	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—liver cancer	1.55e-06	0.000111	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HRAS—liver cancer	1.5e-06	0.000107	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—liver cancer	1.48e-06	0.000106	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—liver cancer	1.46e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—liver cancer	1.45e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—liver cancer	1.44e-06	0.000103	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—liver cancer	1.43e-06	0.000102	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—liver cancer	1.32e-06	9.48e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CA—liver cancer	1.26e-06	9.04e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—liver cancer	1.03e-06	7.39e-05	CbGpPWpGaD
